Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Namrata Vijayvergia"'
Autor:
Angelica Sonzogni, Fabrizio Bianchi, Marco Barella, Jasna Metovic, Mauro Papotti, Giuseppe Pelosi, Namrata Vijayvergia, Yulan Gong, Adriana Albini, Elisa Dama
In the gastro-entero-pancreatic (GEP) tract, neuroendocrine neoplasms (NENs) include well differentiated neuroendocrine tumors (NETs) and high-grade NE carcinomas (NECs), which are thought to make up separate and mutually exclusive tumor entities. Li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4269947b5bbb20f76337011c68dc185
http://hdl.handle.net/2318/1785942
http://hdl.handle.net/2318/1785942
Autor:
Eric A. Ross, Mark Andrake, Namrata Vijayvergia, Roland L. Dunbrack, Jeffrey Swensen, Kyungsuk Jung, Elena Shagisultanova, Qifang Xu, Joanne Xiu, Wafik S. El-Deiry, Avital Lev, Safoora Deihimi, Michael Slifker, Zoran Gatalica
Publikováno v:
Oncotarget
// Safoora Deihimi 1,2,3,7 , Avital Lev 1,2,3 , Michael Slifker 4 , Elena Shagisultanova 3,9 , Qifang Xu 2 , Kyungsuk Jung 5 , Namrata Vijayvergia 3 , Eric A. Ross 4,6 , Joanne Xiu 8 , Jeffrey Swensen 8 , Zoran Gatalica 8 , Mark Andrake 2 , Roland L.
Autor:
Harold A. Harvey, Joanne Xiu, Wafik S. El-Deiry, Sandeep K. Reddy, Angelique Scicchitano, Bora Lim, Namrata Vijayvergia, Zoran Gatalica, Nelson S. Yee
Publikováno v:
Cancer biologytherapy. 16(12)
Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival of 13.1%. Therapies guided by tumor profiling have suggested benefit in advanced cancer. We used a multiplatform molecular profiling (MP) approach to identif
Autor:
Namrata Vijayvergia, Ranee Mehra
Publikováno v:
Cancer chemotherapy and pharmacology. 74(3)
The revolution in individualized therapy for patients with advanced non-small cell lung cancer (NSCLC) has seen the emergence of a number of molecularly targeted therapies for distinct patient molecular subgroups. Activating anaplastic lymphoma kinas
Autor:
Elena Shagisultanova, Joanne Xiu, Raji Shameem, Zoran Gatalica, Wafik S. El-Deiry, Namrata Vijayvergia, Aarti K. Bhatia
Publikováno v:
Journal of Clinical Oncology. 33:e14684-e14684
e14684 Background: BRCA1 or BRCA2 mutations can promote CRC. Repetitive DNA sequences in BRCA1/2 may be impacted by DNA repair defects characteristic of MSI-H tumors that comprise ~15% of CRC. We investigated therapeutically relevant biomarkers in MS